Innoviva (INVA) Cash from Financing Activities (2010 - 2026)

Innoviva's (INVA) quarterly Cash from Financing Activities came in at -$20.1 million in Q1 2026, down 11108.74% YoY from N/an in Q1 2025, and down 264.16% on a QoQ basis from $12.3 million in Q3 2025.

Innoviva (INVA) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Innoviva (INVA) has 17 years of Cash from Financing Activities data on file, last reported at -$20.1 million in Q1 2026.

  • Quarterly Cash from Financing Activities fell 11108.74% year-over-year to -$20.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.4 million (up 77.05% YoY) and the FY2025 annual result came in at $8.6 million, up 163.56% from the prior year.
  • Cash from Financing Activities eased to -$20.1 million in Q1 2026, from $12.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $60.3 million in Q1 2022 to a low of -$157.2 million in Q3 2023.
  • A 5-year average of -$25.6 million and a median of -$9.2 million in 2023 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 383.11% — and 2026, when it plunged 11108.74%.
  • Tracing INVA's Cash from Financing Activities over 5 years: stood at -$45.6 million in 2022, then tumbled by 245.1% to -$157.2 million in 2023, then surged by 91.08% to -$14.0 million in 2024, then jumped by 187.49% to $12.3 million in 2025, then slumped by 264.16% to -$20.1 million in 2026.
  • The last three Cash from Financing Activities figures came in at -$20.1 million (Q1 2026), $12.3 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 2.42 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -6.05 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -207,909.22
7 Royalty Pharma 33.72 Bn 35.84 Bn - -273.15 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 36.24 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 27.18 Mn
10 Innoviva 1.54 Bn 968.79 Mn 90.62 Mn -29.41 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -29.41 Mn
Jun 30, 2026 -29.41 Mn
Mar 31, 2026 -20.15 Mn
Mar 31, 2026 -20.15 Mn
Sep 30, 2025 12.27 Mn
Sep 30, 2025 12.27 Mn
Jun 30, 2025 1.25 Mn
Jun 30, 2025 1.25 Mn
Mar 31, 2025 183,000.00
Mar 31, 2025 183,000.00
Sep 30, 2024 -14.03 Mn
Sep 30, 2024 -14.03 Mn
Jun 30, 2024 -5.07 Mn
Jun 30, 2024 -5.07 Mn
Mar 31, 2024 -9.17 Mn
Mar 31, 2024 -9.17 Mn
Sep 30, 2023 -157.25 Mn
Sep 30, 2023 -157.25 Mn
Jun 30, 2023 -9.21 Mn
Jun 30, 2023 -9.21 Mn